Heterogeneity in the clinical behavior of chronic lymphocytic leukemia (CLL) patients makes it difficult for physicians to accurately identify which patients may benefit from an early or more aggressive treatment strategy and to provide patients with relevant prognostic information. Given the potential efficacy of newer therapies and the desire to treat patients at "optimum" times, it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis. The evolution of risk stratification models has advanced from clinical staging and use of basic laboratory parameters to include relevant biologic and genetic features. This article will review the dramatic progress in prognostication for CLL and will propose statistical modeling techniques to evaluate the utility of these new measures in predictive models to help determine the optimal combination of markers to improve prognostication for individual patients. This discussion will also elaborate which markers and tools should be used in current clinical practice and evaluated in ongoing clinical trials.
Abstract:
Heterogeneity in the clinical behavior of chronic lymphocytic leukemia (CLL) patients makes it difficult for physicians to accurately identify which patients may benefit from an early or more aggressive treatment strategy and to provide patients with relevant prognostic information. Given the potential efficacy of newer therapies and the desire to treat patients at "optimum" times, it is more important than ever to develop sensitive stratification parameters to identify patients with poor prognosis. The evolution of risk stratification models has advanced from clinical staging and use of basic laboratory parameters to include relevant biologic and genetic features. This article will review the dramatic progress in prognostication for CLL and will propose statistical modeling techniques to evaluate the utility of these new measures in predictive models to help determine the optimal combination of markers to improve prognostication for individual patients. This discussion will also elaborate which markers and tools should be used in current clinical practice and evaluated in ongoing clinical trials.
I. Introduction-the problem with being "indolent"
The B-cell malignancies share a common cell lineage but a wide range of clinical, laboratory, molecular, and genetic features. Once grouped together as "subtypes" under the broad term of non-Hodgkin's lymphoma, the classification systems for these diseases have gone through extensive refinement to better distinguish their clinical and biologic characteristics 1 2 .
Traditional teaching labeled diseases that were fatal in weeks to months if untreated as "aggressive" and those that progressed over months to years as "indolent".
Through a major, collaborative, international effort the WHO recently published a consensus classification system which distinguished lymphoid disorders based on a combination of clinical syndromes, morphology, immunophenotype, and genetic features 2 . The WHO Classification added the concept that each disorder represented a separate and distinct disease with CLL and small lymphocytic lymphoma grouped into a single entity (CLL) 2 .
While this categorization no longer distinguishes these diseases as "indolent" or "aggressive", the low-grade B-cell disorders are still evaluated along these lines 3 . These disorders are often considered chronic diseases of the elderly and patients are thought likely to die of unrelated causes. These assumptions are incorrect, and, to a certain extent, have hampered progress in this field.
For CLL, the median age of diagnosis is 65-68 years old 4 . Some patients experience a slowly progressive clinical course but the majority will eventually progress and have fatal outcomes 4 5 . Importantly, significant subsets of early stage patients with CLL become active 4 6 7,8 , are refractory to treatment 7 , experience infectious or autoimmune complications, and have more rapidly fatal outcomes than anticipated.
This clinical heterogeneity emphasizes the problem of considering CLL "indolent" and, in the era of more efficacious therapy, highlights the need to improve our ability to identify patients with poor prognosis. Recent trials of monoclonal antibodies in combination with chemotherapy have reported previously unattained response rates 9 10 . These therapies frequently reduce disease burden to levels detectable only by flow cytometry or molecular methods and raise the possibility of cures 11 . Additionally, progress in the field of autologous and allogeneic stem cell transplantation have led to studies of transplant in younger patients with refractory or aggressive disease 12 .
For decades, "watchful waiting" has been the standard of care for patients with early stage CLL. This approach has focused on minimizing toxicity for the minority of patients whose disease may never evoke clinical symptoms. The recent progress in the treatment raises critical new questions for CLL patients. Which early stage patients should be treated? Which patients should receive more aggressive therapy? Who should undergo stem-cell transplant?
These questions cannot be answered without accurate and precise prognostication for individual patients. For the purpose of this review, we term laboratory measures used to predict outcomes as "prognostic markers" (e.g. Beta 2 microglobulin) and classification systems built on multiple measures or calculations "prognostic tools" (e.g. staging; lymphocyte doubling time).
Risk stratification models will refer to the use of statistical modeling to validate integration of multiple markers and tools to improve prognostic precision.
II. Historic Perspective and Update

STAGING
Clinical staging systems based on disease burden were the initial prognostic tool in CLL.
In 1975, Rai and colleagues developed a seminal set of clinical "staging" criteria for CLL based on the presence of lymphadenopathy, organomegaly (spleen and liver), and cytopenias 13 .
Importantly, Rai demonstrated a correlation between Rai stage and survival 13 . The original Rai staging system was later revised from a 5-tier system (0-IV) to a 3-tier system that categorized Table 1 . Other demographic and clinical factors including age 5 13 , sex 5 13 15 , and performance status 17 have been shown to impact prognosis, although the magnitude and significance of age and sex independent of stage is inconsistent across series 18 . Bone marrow histologic pattern (diffuse involvement vs. all other patterns) is an accepted adjunct to staging in CLL and has the potential to identify patients with greater likelihood of progression and shorter survival independent of stage 19 20 .
Over the last 30 years, significant changes in the pattern of diagnosis of CLL have occurred with a shift from patients presenting with bulky nodes and cytopenias, to the detection of asymptomatic individuals identified by an elevated lymphocyte count on automated differential blood counts 4 . Using immunophenotyping and flow cytometry, the diagnosis of CLL has also become more precise. We are now able to more easily distinguish CLL from mantle cell lymphoma and T-cell disorders. Furthermore, it is now recognized that a subset of early stage CLL patients have a disease that will rapidly evolve to a more advanced, refractory, and fatal disease 4 5 6 7 8 . Rai and Binet staging lack the ability to prospectively identify the rapidly evolving patient from those destined to remain with early stage for decades. For patients with more advanced disease, these staging systems do not distinguish those who will be stable from the more aggressive cohort.
LYMPHOCYTE DOUBLING TIME:
One calculation that may be associated with meaningful differences in disease kinetics is the lymphocyte doubling time (LDT Technological advancements have led to breakthroughs in diagnosis and targeted therapy for several hematologic malignancies 30 31 . The application of fluorescent in situ hybridization (FISH) and the recent development of robust methods for genetic analysis are rapidly increasing our understanding of malignancy. Microarray analysis allows genomic assessment that can improve categorization of tumor type (class prediction) and identify previously unrecognized tumor subtypes (class discovery) 32 . Global genetic analysis can also reveal clues to the early biologic defects underlying malignant transformation and identify novel targets for treatment.
These techniques have generated a period of linear growth in the study of CLL biology, particularly in the search for risk stratification markers ( Figure I ). The latter now include assays for cytokines, enzymes, soluble proteins, cellular receptors, markers of angiogenesis, and recurring genetic defects. These parameters define differences in underlying disease biology that can be used with clinical tools to identify patients with more aggressive disease.
IMMUNOGLOBULIN VARIABLE HEAVY CHAIN (IgV H ) MUTATION STATUS
Historically, CLL B-cells were believed to represent a leukemic transformation of naïve Blymphocytes that had not undergone germinal center antigen exposure and subsequent somatic mutation of their immunoglobulin (Ig) genes. Several recent studies have found that approximately 50% of CLL clones exhibit somatic mutation of their immunoglobulin chains which suggests that some CLL clones arise from post-germinal center, "memory" B-cells 33 . In 1999, two publications simultaneously reported on the prognostic significance of IgV H mutational status in CLL 7 8 . These studies defined patients with >2% difference in nucleotide sequences from germline cells as having a mutated clone and those with 2% as non-mutated.
When patients with Binet stage A disease were stratified according to IgV H gene mutational status, significant survival differences were observed. The median survival was 8-9 years for patients with non-mutated IgV H genes (germline cells) but beyond 24 years for patients with somatically mutated IgV H genes. These reports also noted a relationship between non-mutated IgV H genes and the need for chemotherapy 7 , response to chemotherapy 7 , and unfavorable cytogenetic abnormalities detected by FISH 8 .
Although the biologic significance of IgV H gene mutation status is unclear 34 , the prognostic significance of IgV H mutation status has been confirmed 23 On balance, CD38 appears to be a useful and readily measurable prognostic marker.
However, it has limitations due to differences in CD38 expression for individual patients over time 35 38 45 46 , and it is not a surrogate for IgV H mutation status. Confirmation of the prognostic significance of bimodal CD38 expression may further refine the ability of this marker to identify patients with aggressive disease 50 . Tables II and III review the median survival of CLL patients by Ig V H and CD38 status in aggregate and by disease stage.
CHROMOSOME ANALYSIS:
Most CLL cells are G 0 phase cells which accumulate primarily through prolonged survival due to defects in apoptosis 52 . The small number of dividing leukemic cells in CLL makes conventional cytogenetic testing problematic, and mitogen stimulation of CLL B-cells is required to achieve an adequate number of metaphases for analysis 53 . Chromosome abnormalities can be detected in 30-50% of patients with CLL using this technique, and early studies identified trisomy 12, 11q-, and 17p-as poor prognostic markers 54 55 56 .
In 1990, a pooled analysis reported on the prognostic significance of chromosome analysis using conventional cytogenetics in 433 patients with CLL 56 . Patients with a normal karyotype or 13q-abnormalities had a better survival than patients with trisomy 12, or a complex karyotype. After controlling for age and stage, the prognostic significance of chromosome abnormalities by conventional cytogenetic testing remained significant.
With the development of interphase FISH techniques, it became possible to detect selected chromosome abnormalities in non-dividing cells. While more sensitive and specific than conventional cytogenetics, FISH does not completely evaluate all chromosomes so one must "know what one's looking for". FISH probes in CLL found chromosomal abnormalities were more common than detected using conventional cytogenetics and had a different distribution (13q-, 11q-more common and +12 less common) 56 57 58 .
The prognostic significance of chromosome analysis by FISH was studied using a comprehensive set of probes in 325 patients with CLL 58 . Chromosome abnormalities were identified in 82% of patients: 55% of patients had a 13q-, 18% 11q-, 16% trisomy 12, 7% 17p-, 6% 6q-, and 29% of patients had more than one chromosome abnormality. On multivariate analysis 17p-and 11q-were identified as variables associated with shorter overall survival. A hierarchical survival model constructed after regression analysis was used to assign patients to risk categories (Table IV) . Comprehensive reviews of the significance of chromosome abnormalities in CLL have recently been published 59 .
Others subsequently evaluated the relationship between FISH, IgV H mutation status, and CD38 expression. In the largest reported study mutational status, CD38 status, and FISH detectable chromosome defects were evaluated in 325 consecutive patients 35 . The P53 gene, located on the short arm of chromosome 17, plays an integral role in inducing apoptosis or cell cycle arrest after DNA damage. In CLL, a functional p53 pathway is an important indicator of responsiveness to purine nucleoside analogues perhaps explaining the prognostic importance of 17p-abnormalities 61 62 . Multiple mechanisms by which p53 dysregulation may occur include direct p53 mutation due to abnormalities of chromosome 17p
and inactivation by regulator genes, some of which reside on chromosome 11q 58 63 . Since, abnormal p53 function is present in a larger subset of patients with CLL (26%) than abnormalities of chromosome 17 (7%) by FISH analysis, some have proposed functional assays of p53 may be a better prognostic marker than identifying abnormalities on chromosome 17 or 11 35 40 58 .
To evaluate the interaction between mutational status, CD38 status, and p53 function, these variables were explored using an assay of p53 function based on the response of CLL Bcells to ionizing radiation 40 . P53 function was abnormal in roughly 25% of patients; and p53 function, IgV H mutation status, and CD38 status all had prognostic significance on univariate analysis. Importantly, all the patients with p53 dysfunction also had non-mutated IgV H genes 40 .
Immunohistochemical assessment of p53 protein expression may also have prognostic significance in CLL 28, 64 .
New chromosomal abnormalities can be acquired by the CLL clone during the course of disease leading to the concept of "clonal evolution" 45 57 60 . and, on retrospective analysis, untreated patients with indolent disease could be separated into two prognostic groups based on their initial serum TK. In a more recent study of 113 patients with CLL TK was an independent prognostic variable on multivariate analysis, however this study did not include assessment of IgV H mutation status, CD38, or chromosome analysis by FISH 17 . Later, these same investigators reported on the significance of TK in 122 untreated CLL patients 66 . When Binet stage A patients were stratified by TK level, median progression free survival was 9 months (range 5-13 months) for patients with high serum TK levels (>7.1U/L) compared to 49 months (range 24-74 months) for patients with low serum TK levels (p<0.001).
Another recent study reported on the relationship of TK and mutation status and found that a TK level >15 U/L was a strong predictor of non-mutated IgV H genes (odds ratio 31.7) with a positive predictive value of 86% 23 . Others have reported a relationship between TK levels and LDT, markers of disease burden (ALC), and markers of cell turnover (LDH, Beta 2 microglobulin) 67 68 . In one retrospective review of 188 patients, serum TK was a significant predictor of both survival and response to treatment 68 . Assays for TK are feasible and commercially available making it a potentially widely available and useful prognostic marker.
IV. Other Candidates for Prognostic Markers: GENE EXPRESSION PROFILE ANALYSIS: ROADMAP TO OTHER PROGNOSTIC
MARKERS
Several recent studies have employed gene expression profiling (GEP) analysis for the simultaneous evaluation of the expression of multiple genes 69 70 . The rationale for the use of genomics-based technology is to render a more detailed and comprehensive molecular view of human cancers. Reviews of analytic methods and clinically relevant breakthroughs in hematologic malignancies using this technique have recently been published 71 .
Several investigators have performed unsupervised analysis using DNA microarrays in CLL. These studies found a gene signature common to all CLL cells independent of the IgV H mutation status implying that there is a common cell of origin and/or mechanism leading to malignant transformation 70 72 73 74 . Supervised analysis of GEP by IgV H status, however, revealed that certain restricted sets of genes were able to discriminate between the non-mutated and mutated type clones 72 73 . These genes may reveal the molecular map/pathways that leads to the evolution of the CLL B-cell 69 72 73 .
Using immunoblot assays to confirm results from GEP, investigators found the gene encoding zeta-associated protein 70 (ZAP-70), a tyrosine kinase required for T-cell receptor (TCR) signaling normally expressed in T cells, was expressed in 100% patients with nonmutated but only 10% of those with mutated IgV H genes 75 . Other studies using supervised analysis of GEP reported ZAP-70 expression is also found to be elevated in CD38+ patients 70 and that ZAP-70 may play a role in CD38 signaling 76 . A recent report of GEP in 107 patients with CLL confirmed that, of the genes studied, ZAP-70 was the single gene best able to distinguish IgV H mutation status -correctly predicting mutation status in 93% of patients 69 .
The ability of ZAP-70 to predict shorter time to treatment was also similar to IgV H gene mutation status.
In a retrospective series, ZAP-70 expression as determined by flow cytometry was evaluated as a surrogate for IgV H mutation status 77 . 77 . ZAP-70 expression did not change on sequential analysis and it was an independent prognostic marker for overall survival 77 . The estimated median survival for Binet A patients who were ZAP-70+ was 90 months while median survival had not been reached in ZAP-
70-patients (median follow-up 63 months).
While ZAP-70 is a promising prognostic marker, a number of questions remain. As a surrogate for mutation status, the test characteristics of the flow cytometry ZAP-70 assay
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(sensitivity 91%; specificity 100%) are nearly identical to the original reports of CD38 flow cytometry (sensitivity 85%; specificity 100%) which also reported no variation on sequential analysis 7 77 . One small series of sequential ZAP-70 analysis by flow cytometry found 2/16 patients had a change in ZAP-70 status on serial testing using the 20% threshold and 2 other patients had large changes in the percent of CLL B-cells expressing ZAP-70 78 . The 20% cutoff to classify cells ZAP-70+ is arbitrary and the optimal cutoff remains to be determined 77 . ZAP-70
detection by flow cytometry is a technically difficult assay for an intracellular antigen that requires the cell membrane be permeabilized 77 . If ZAP-70 is confirmed as an important prognostic variable for CLL patients, the stability and optimal method of detection will need to be determined 69 78 77 . Table V reports the sensitivity and specificity of markers proposed as surrogates for IgV H mutation status.
MARKERS OF ANGIOGENESIS
Angiogenesis, the growth of new capillaries from preexisting blood vessels, has increasingly been recognized as an important process in the growth of solid tumors 79 , and similar observations have linked angiogenesis with tumor growth in various hematologic malignancies 80 . Early studies in CLL revealed bone marrow microvessel density correlates with disease stage 81 , and subsequent work found a high bone marrow microvessel count identifies patients with a shorter progression free survival 82 . Other reports suggest serum and urine levels of pro-angiogenic factor are increased in CLL 82 83 .
Several preliminary investigations have explored the relationship between vascular factors and survival in CLL. Vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis and is believed to be a significant mediator of tumor angiogenesis 84 . Serum VEGF levels in 68 patients with CLL and 31 control patients were found to be similar. Patients with Binet Stage A or Rai Stage I-II who had serum VEGF levels greater than the median, however, had significantly shorter progression free survival 84 . In aggregate these results suggest that angiogenesis may be an important process in the pathogenesis of CLL and could provide important early clues about patients destined to have more aggressive disease. If validated, the measurement of serum VEGF could help discriminate high risk early stage CLL patients.
OTHER:
Although beyond the scope of this review, several other cytokines, enzymes, and molecular markers including IL6 27 85 , IL10 27 , TNF 86 , intracellular Bcl-2 87 , and soluble intracellular adhesion molecule 1 (ICAM1) 88 An important caveat to these approaches is that a valid model requires a very large data set. Such models have been constructed for prostate cancer and soft tissue sarcoma, with inclusion of over 1,000 and 2,000 patients, respectively 95, 96 
Conclusion:
Future studies of CLL using molecular biologic techniques will continue to refine our Results of PUBMED search by year using the key words "CLL" and "prognosis". Median survival in months by Rai and Binet stage as reported in initial publications of these staging systems for CLL. * = from time of enrollment on trial ** = used cutoff of 20% rather than 30% to determine CD38 positivity *** = Non-significant difference between groups; **** = Used 3 cutoffs to classify IgV H gene mutation status (<2%, 2-5%,>5%) data shown for <2% and >5%; ***** = N for IgV H analysis=108; N for CD38 analysis=148; Study reported 3 categories of CD38 status: negative; positive; and bi-modal CD38 expression.
Data presented for CD38 negative and positive groups based on 30% cut-off. See text discussion. 1 Recommendations for clinicians in "routine" evaluation of their CLL patients. 2 Recommendations for risk stratification parameters that should be measured in clinical trials where formal biostatistical analysis can be performed on well-characterized groups of CLL patients. 3 Including both marrow angiogenesis levels as well as serum levels of pro and antiangiogenic factors 
